Backgroud: Short QT syndrome (SQTs) is a genetically determined disorder,characterized by short QT interval,increased susceptibility to malignant tachyarrhythmias and sudden cardiac death.To date,the pharmacotherapy of SQTs is mainly relate to the SQT1 caused by N588K mutation in KCNH2 gene.Objectives: The purpose of this study was to evaluate the efficacy and remediation role of various antiarrhythmic drugs to SQTs caused by E428G mutation in SCN5A gene in Chinese patients which was discovered by our research group recently.